154 related articles for article (PubMed ID: 38630860)
1. Design of dry powder inhalers to improve patient outcomes: it's not just about the device.
Weers JG
Expert Opin Drug Deliv; 2024 Mar; 21(3):365-380. PubMed ID: 38630860
[TBL] [Abstract][Full Text] [Related]
2. Dry powder inhalers in COPD, lung inflammation and pulmonary infections.
Muralidharan P; Hayes D; Mansour HM
Expert Opin Drug Deliv; 2015 Jun; 12(6):947-62. PubMed ID: 25388926
[TBL] [Abstract][Full Text] [Related]
3. The ELLIPTA® Dry Powder Inhaler: Design, Functionality, In Vitro Dosing Performance and Critical Task Compliance by Patients and Caregivers.
Grant AC; Walker R; Hamilton M; Garrill K
J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):474-85. PubMed ID: 26372466
[TBL] [Abstract][Full Text] [Related]
4. In Vitro Dosing Performance of the ELLIPTA® Dry Powder Inhaler Using Asthma and COPD Patient Inhalation Profiles Replicated with the Electronic Lung (eLung™).
Hamilton M; Leggett R; Pang C; Charles S; Gillett B; Prime D
J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):498-506. PubMed ID: 26372465
[TBL] [Abstract][Full Text] [Related]
5. Dose emission characteristics of placebo PulmoSphere® particles are unaffected by a subject's inhalation maneuver.
Weers J; Ung K; Le J; Rao N; Ament B; Axford G; Maltz D; Chan L
J Aerosol Med Pulm Drug Deliv; 2013 Feb; 26(1):56-68. PubMed ID: 22691109
[TBL] [Abstract][Full Text] [Related]
6. The clinical relevance of dry powder inhaler performance for drug delivery.
Demoly P; Hagedoorn P; de Boer AH; Frijlink HW
Respir Med; 2014 Aug; 108(8):1195-203. PubMed ID: 24929253
[TBL] [Abstract][Full Text] [Related]
7. Dry powder inhalation: past, present and future.
de Boer AH; Hagedoorn P; Hoppentocht M; Buttini F; Grasmeijer F; Frijlink HW
Expert Opin Drug Deliv; 2017 Apr; 14(4):499-512. PubMed ID: 27534768
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
Daley-Yates PT; Mehta R; Chan RH; Despa SX; Louey MD
J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):279-89. PubMed ID: 24074143
[TBL] [Abstract][Full Text] [Related]
9. A review of co-milling techniques for the production of high dose dry powder inhaler formulation.
Lau M; Young PM; Traini D
Drug Dev Ind Pharm; 2017 Aug; 43(8):1229-1238. PubMed ID: 28367654
[TBL] [Abstract][Full Text] [Related]
10. The importance of inhaler devices: the choice of inhaler device may lead to suboptimal adherence in COPD patients.
Darbà J; Ramírez G; Sicras A; Francoli P; Torvinen S; Sánchez-de la Rosa R
Int J Chron Obstruct Pulmon Dis; 2015; 10():2335-45. PubMed ID: 26604733
[TBL] [Abstract][Full Text] [Related]
11. The Impact of Inspiratory Flow Rate on Drug Delivery to the Lungs with Dry Powder Inhalers.
Weers J; Clark A
Pharm Res; 2017 Mar; 34(3):507-528. PubMed ID: 27738953
[TBL] [Abstract][Full Text] [Related]
12. Numerical simulation of the effect of inhalation parameters, gender, age and disease severity on the lung deposition of dry powder aerosol drugs emitted by Turbuhaler®, Breezhaler® and Genuair® in COPD patients.
Horváth A; Farkas Á; Szipőcs A; Tomisa G; Szalai Z; Gálffy G
Eur J Pharm Sci; 2020 Nov; 154():105508. PubMed ID: 32836137
[TBL] [Abstract][Full Text] [Related]
13. Understanding Dry Powder Inhalers: Key Technical and Patient Preference Attributes.
Levy ML; Carroll W; Izquierdo Alonso JL; Keller C; Lavorini F; Lehtimäki L
Adv Ther; 2019 Oct; 36(10):2547-2557. PubMed ID: 31478131
[TBL] [Abstract][Full Text] [Related]
14. Effect of Disease Severity in Asthma and Chronic Obstructive Pulmonary Disease on Inhaler-Specific Inhalation Profiles Through the ELLIPTA® Dry Powder Inhaler.
Prime D; de Backer W; Hamilton M; Cahn A; Preece A; Kelleher D; Baines A; Moore A; Brealey N; Moynihan J
J Aerosol Med Pulm Drug Deliv; 2015 Dec; 28(6):486-97. PubMed ID: 26372467
[TBL] [Abstract][Full Text] [Related]
15. The dry powder inhaler features of the Easyhaler that benefit the management of patients.
Chrystyn H; Lavorini F
Expert Rev Respir Med; 2020 Apr; 14(4):345-351. PubMed ID: 32013627
[No Abstract] [Full Text] [Related]
16. Assessment of satisfaction with different dry powder inhalation devices in Greek patients with COPD and asthma: the ANASA study.
Zervas E; Samitas K; Gaga M
Int J Chron Obstruct Pulmon Dis; 2016; 11():1845-55. PubMed ID: 27540287
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature.
Brocklebank D; Ram F; Wright J; Barry P; Cates C; Davies L; Douglas G; Muers M; Smith D; White J
Health Technol Assess; 2001; 5(26):1-149. PubMed ID: 11701099
[TBL] [Abstract][Full Text] [Related]
18. Physical stability of dry powder inhaler formulations.
Shetty N; Cipolla D; Park H; Zhou QT
Expert Opin Drug Deliv; 2020 Jan; 17(1):77-96. PubMed ID: 31815554
[No Abstract] [Full Text] [Related]
19. Design and physicochemical characterization of advanced spray-dried tacrolimus multifunctional particles for inhalation.
Wu X; Hayes D; Zwischenberger JB; Kuhn RJ; Mansour HM
Drug Des Devel Ther; 2013; 7():59-72. PubMed ID: 23403805
[TBL] [Abstract][Full Text] [Related]
20. Formulation techniques for high dose dry powders.
Brunaugh AD; Smyth HDC
Int J Pharm; 2018 Aug; 547(1-2):489-498. PubMed ID: 29778822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
